Division of Gastroenterology, Hepatology and Nutrition, Mattel Children's Hospital, Department of Pediatrics, David Geffen School of Medicine, UCLA, Los Angeles, California 90095-1752, USA.
Curr Opin Organ Transplant. 2011 Jun;16(3):306-11. doi: 10.1097/MOT.0b013e32834670eb.
To provide an overview of how intravenous omega-3 fatty acids (O3FAs) have been used to prevent and treat pediatric intestinal failure-associated liver disease (IFALD). This review will introduce the most recent and relevant human and basic science data on the topic, and comment on how alterative lipid emulsions may alter the future course of children with IFALD.
Animal and cohort studies along with case reports have reported that Omegaven (Fresenius Kabi, Bad Homburg vdh, Germany), which contains high concentrations of O3FAs, can reverse IFALD and prevent the need for combined liver-intestinal transplantation and death. Laboratory work and human data support that O3FAs increase antioxidant activity and biliary flow and decrease inflammation and de-novo lipogenesis. Many postulate that intravenous O3FAs may positively affect cognitive function, immune status, nutrition, and intestinal adaptation and decrease the risk of adult-onset chronic diseases. Although evidence continues to mount to support the use of parenteral O3FA products, questions remain.
O3FAs have altered the way in which basic scientists and clinicians approach IFALD. Knowledge gaps, however, still exist before this therapy can be considered standard of care.
提供静脉用 ω-3 脂肪酸（O3FA）在预防和治疗儿科肠衰竭相关肝病（IFALD）中的应用概述。本综述将介绍该主题的最新和最相关的人体和基础科学数据，并评论替代脂质乳剂如何改变 IFALD 患儿的未来病程。
动物和队列研究以及病例报告报告称，含有高浓度 O3FA 的欧玛泽（德国法尔松尼乌斯卡比公司，巴特洪堡）可逆转 IFALD 并防止需要联合肝肠移植和死亡。实验室工作和人体数据支持 O3FA 增加抗氧化活性和胆汁流量，减少炎症和从头脂肪生成。许多人推测，静脉用 O3FA 可能对认知功能、免疫状态、营养、肠道适应和降低成年后慢性疾病的风险产生积极影响。尽管越来越多的证据支持使用肠外 O3FA 产品，但仍存在一些问题。
O3FA 改变了基础科学家和临床医生处理 IFALD 的方式。然而，在这种治疗方法被认为是标准护理之前，仍然存在知识空白。
